Myriad Genetics Says USPTO Issued Third Patent For Molecular Residual Disease With Early Priority Date
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics announced that the United States Patent and Trademark Office (USPTO) has issued a third patent for its molecular residual disease technology, which has an early priority date. This development strengthens Myriad's intellectual property portfolio in the field.
October 01, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Myriad Genetics has been granted a third patent for its molecular residual disease technology, which could enhance its competitive edge and intellectual property strength.
The issuance of a third patent with an early priority date for Myriad Genetics' molecular residual disease technology is a significant development. It enhances the company's intellectual property portfolio, potentially providing a competitive advantage in the biotech industry. This could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90